The above average performance in the last financial year has prompted Cocrystal Pharma Inc (OTCBB:COCP) to make some important changes in its top management team. The first change has come in the form of Jeffrey Meckler, who has been named as the new interim Chief Executive Officer of the company.
Insights On The Matter:
Cocrystal Pharma Inc (OTCBB:COCP) is known for developing various novel antiviral therapeutics for life-threatening human diseases. The primary reason behind the appointment of Jeffrey Meckler is nothing but the retirement of the current CEO of the company. Dr. Gary Wilcox has decided to step down from his current position which has prompted the company to take a strong decision to ensure that all the operations keep running without any hassle. The appointment of Mr. Meckler has become effective after the signing of Form 10-K.
As Dr. Wilcox has resigned from his current role, the company has decided to appoint him as the new Vice Chairman of the Board of Directors. He will continue to take part in the decision-making and advisory process. Even after joining as the CEO of Cocrystal, Meckler will continue his existing position as the Director of the company. The newest addition to the Board of Directors is Dr. Raymond F. Schinazi, who will act as the Chairman of the Board.
Meckler comes with more than 25 years of experience in the Life Science field. He has worked in many companies over these years. Meckler spent more than 17 years at Pfizer Inc. and worked in diverse profiles including Manufacturing, Market Research, Systems and Corporate Finance. He worked as the Principal Executive Officer at QLT Inc. before joining Cocrystal.
The entire management team of Cocrystal is delighted to welcome Meckler and hopes that he will use his expertise and experience for the growth of Cocrystal in the near future.
